University of Pennsylvania, Perelman School of Medicine, Philadelphia, USA.
The Lake Erie School of Osteopathic Medicine, Erie, USA.
BMC Cardiovasc Disord. 2023 Sep 7;23(1):440. doi: 10.1186/s12872-023-03456-9.
Heart failure (HF) is one of the most common reasons for hospital admission and is a major cause of morbidity, mortality, and increasing health care costs. The EMPOWER study was a randomized trial that used remote monitoring technology to track patients' weight and diuretic adherence and a state-of-the-art approach derived from behavioral economics to motivate adherence to the reverse monitoring technology.
The goal was to explore patient and clinician perceptions of the program and its impact on perceived health outcomes and better understand why some patients or clinicians did better or worse than others in response to the intervention.
This was a retrospective qualitative study utilizing semi-structured interviews with 43 patients and 16 clinicians to understand the trial's processes, reflecting on successes and areas for improvement for future iterations of behavioral economic interventions.
Many patients felt supported, and they appreciated the intervention. Many also appreciated the lottery intervention, and while it was not an incentive for enrolling for many respondents, it may have increased adherence during the study. Clinicians felt that the intervention integrated well into their workflow, but the number of alerts was burdensome. Additionally, responses to alerts varied considerably by provider, perhaps because there are no professional guidelines for alerts unaccompanied by severe symptoms.
Our qualitative analysis indicates potential areas for additional exploration and consideration to design better behavioral economic interventions to improve cardiovascular health outcomes for patients with HF. Patients appreciated lottery incentives for adhering to program requirements; however, many were too far along in their disease progression to benefit from the intervention. Clinicians found the amount and frequency of electronic alerts burdensome and felt they did not improve patient outcomes.
ClinicalTrials.gov Identifier: NCT02708654.
心力衰竭(HF)是住院的最常见原因之一,是发病率、死亡率和不断增加的医疗保健费用的主要原因。EMPOWER 研究是一项随机试验,使用远程监测技术来跟踪患者的体重和利尿剂的使用情况,并采用行为经济学的最新方法来激励患者使用反向监测技术。
目的是探讨患者和临床医生对该计划的看法及其对感知健康结果的影响,并更好地了解为什么有些患者或临床医生对干预的反应好于或差于其他患者或临床医生。
这是一项回顾性定性研究,对 43 名患者和 16 名临床医生进行了半结构化访谈,以了解试验的过程,反思成功之处和改进之处,为未来行为经济学干预措施的迭代提供参考。
许多患者感到得到了支持,他们对干预措施表示赞赏。许多患者还对彩票干预措施表示赞赏,虽然对于许多受访者来说,这并不是参加的激励因素,但它可能会增加研究期间的依从性。临床医生认为该干预措施很好地融入了他们的工作流程,但提醒的数量很多。此外,由于没有严重症状伴随的提醒的专业指南,提供者之间的响应差异很大。
我们的定性分析表明,需要进一步探索和考虑一些潜在的领域,以设计更好的行为经济学干预措施,改善 HF 患者的心血管健康结果。患者对坚持项目要求的彩票激励措施表示赞赏;然而,许多患者的疾病进展已经到了无法从干预中受益的地步。临床医生认为电子提醒的数量和频率负担过重,并且觉得这些提醒并不能改善患者的治疗效果。
ClinicalTrials.gov 标识符:NCT02708654。